MELBOURNE, AUSTRALIA / ACCESSWIRE / March 19, 2015 / Propanc Health Group Corporation (PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced it has commenced the second stage of its POP1 research program with the University of Jaen, Spain, to investigate further the anti-cancer effects and cellular mechanisms associated with proenzymes as a treatment for cancer. The aim is to identify new patentable drugs as back up compounds to the Company's lead product, PRP.

"Jaen, Granada and Bath Universities were all significant contributors to our initial research, when we previously undertook laboratory studies to elucidate how PRP works and to identify patentable opportunities. Not only did we end up jointly filing a patent with Bath University around the world, which we were assigned the commercial rights to, but were able to publish key scientific discoveries in a peer reviewed journal. Our lead experimentalist, Dr Macarena Peran, did an excellent job in bringing these Research Institutions together and I look forward to collaborating with her over the course of this year and beyond," said James Nathanielsz, Propanc's Chief Executive Officer. "Our intention is to aggressively screen and develop new compounds for future development as a back up to our lead product, PRP. We hope to establish an exciting new treatment class in oncology which complements existing treatments and helps reduce the threat of tumor recurrence and metastasis. This is part of our strategic plan."

About Propanc:

We are a development stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our leading products are variations upon our novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we intend to submit our proenzyme treatment to the rigorous, formal non-clinical and clinical development and trial processes required to obtain the regulatory approval necessary to commercialize it and any product(s) derived and/or to be derived therefrom.

In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In the future, we intend to development our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, please visit: www.propanc.com.

Forward-looking Statements:

Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.

Contact:

Regal Consulting
Tel: 702 - 575 - 9157

SOURCE: Propanc Health Group Corporation